Answers are grounded in this paper and cite their sources.
Resistance to enzalutamide remains a major challenge in advanced prostate cancer, but the mechanisms linking epitranscriptomic regulation to apoptotic escape remain incompletely understood. By integrating MeRIP-seq and RNA-seq analyses of parental and enzalutamide-resistant prostate cancer cells, we identified the deubiquitinase YOD1 as a candidate mediator of resistance. YOD1 depletion enhanced enzalutamide-induced apoptosis and suppressed resistant tumor growth in vitro and in vivo. Mechanistically, METTL3-dependent m6A modification at A1360 promoted the association of YOD1 mRNA with IGF2BP2, thereby enhancing transcript stability and YOD1 expression. YOD1 associated with Bcl-xL and limited its K48-linked ubiquitination and proteasomal degradation. Catalytic-mutant and genetic rescue experiments supported the requirement for YOD1 deubiquitinase activity and positioned Bcl-xL as a functional downstream effector. Pharmacological inhibition of Bcl-xL with A-1,155,463 enhanced the response to enzalutamide in cellular and resistant xenograft models. In addition, immunohistochemical analysis of prostate cancer specimens revealed positive associations among METTL3, YOD1 and Bcl-xL protein abundance. Together, these findings support an m6A-deubiquitinase-Bcl-xL regulatory cascade that contributes to apoptotic resistance during enzalutamide treatment. This pathway may represent a potential therapeutic vulnerability, although its clinical relevance requires further validation.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: